Results 31 to 40 of about 295,503 (301)

Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease

Neurobiology of Disease, 2011
Cell adhesion molecules might play an important role in the inflammatory mechanisms associated with neurodegeneration. We have previously observed, in rats, that subcutaneous injection of complete Freund's adjuvant (CFA), a pro-inflammatory agent that ...
Marie-Therese Armentero, Giovanna Levandis, Eleonora Bazzini, Silvia Cerri, Cristina Ghezzi, Fabio Blandini   +5 more
doaj   +1 more source

Musculoskeletal Pain in Parkinson's Disease

Frontiers in Neurology, 2022
BackgroundMusculoskeletal pain is commonly experienced in patients with Parkinson's disease (PD). Few studies have investigated the clinical characteristics and risk factors associated with musculoskeletal pain.ObjectivesTo investigate the distribution ...
Jun Li, Jun Li, Ben-Fan Zhu, Zhu-Qin Gu, Zhu-Qin Gu, Hui Zhang, Hui Zhang, Shan-Shan Mei, Shan-Shan Mei, Shao-Zhen Ji, Shao-Zhen Ji, Shu-Ying Liu, Shu-Ying Liu, Chao Han, Chao Han, Huai-Zhen Chen, Piu Chan, Piu Chan, Piu Chan, Piu Chan, Piu Chan   +20 more
doaj   +1 more source

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment

Clinical Parkinsonism & Related Disorders, 2023
Dopamine agonists (DAs) have demonstrated efficacy for the treatment of Parkinson’s disease (PD) but are limited by adverse effects (AEs). DAs can vary considerably in their receptor subtype selectivity and affinity, chemical composition, receptor ...
Stuart H. Isaacson, Robert A. Hauser, Rajesh Pahwa, David Gray, Sridhar Duvvuri   +4 more
doaj   +1 more source

Everyday walking with Parkinson's disease: understanding personal challenges and strategies [PDF]

, 2008
PURPOSE: This qualitative study was designed to explore the personal experience of everyday walking with Parkinson's disease (PD), the challenges and the strategies employed to compensate for difficulties, to help contextualise the scientific knowledge ...
Birleson, Angela, Hetherington, Victoria, Jones, Diana, Kwakkel, Gert, Nieuwboer, Alice, Rochester, Lynn, van Wegen, Erwin, Willems, Anne-Marie   +7 more
core   +2 more sources

Severe Constipation in Parkinson's Disease and in Parkinsonisms: Prevalence and Affecting Factors

Frontiers in Neurology, 2019
Background: constipation is one of the most common and disabling non-motor symptoms of Parkinson Disease (PD) and Parkinsonisms (PS). Few studies evaluate the difference of prevalence between PD and PS and the cause leading to a severe constipation in ...
Giuseppe Frazzitta, Davide Ferrazzoli, Annarita Folini, Grazia Palamara, Roberto Maestri   +4 more
doaj   +1 more source

Treatment of dystonia and tics

Clinical Parkinsonism & Related Disorders, 2020
Treatment of dystonia and tics continues to evolve. In dystonia, while oral agents such as benzodiazepines, baclofen and anticholinergics remain in use, botulinum toxin (BoNT) continues to be regarded as the treatment of choice for focal and segmental ...
Steven Bellows, Joseph Jankovic
doaj   +1 more source

Understanding health care needs among Veterans with Parkinson's disease: A survey study

Frontiers in Neurology, 2022
Among Veterans, it is estimated that 110,000 are living with Parkinson's disease (PD) in the United States. Whether or not Veterans living with PD are enrolled in the Veterans Health Administration (VHA), they may require special considerations when it ...
Megan Feeney, John Duda, Amie Hiller, Amie Hiller, Jay Phillips, Christiana Evers, Nicole Yarab, Veronica Todaro, Lydia Rader, Sheera Rosenfeld   +9 more
doaj   +1 more source

Pain-motor integration in the primary motor cortex in Parkinson's disease [PDF]

, 2017
In Parkinson's disease (PD), the influence of chronic pain on motor features has never been investigated. We have recently designed a technique that combines nociceptive system activation by laser stimuli and primary motor cortex (M1) activation through ...
Berardelli, Alfredo, Biasiotta, A, Cruccu, Giorgio, Di Santo, A, DI STASIO, Flavio, LA CESA, Silvia, Leone, Caterina, Marsili, Luca, Suppa, Antonio, Truini, Andrea   +9 more
core   +1 more source

Amantadine-based combination therapy of Parkinson’s disease to prevent fluctuation and dyskinesia – experiences from a Parkinson outpatient clinic

Frontiers in Aging Neuroscience
BackgroundThe standard therapy of Parkinson’s disease consists in supplementing the depleted dopamine with oral levodopa. The disadvantages of the levodopa monotherapy – comparable to other dopaminergic substances – are the dose-dependent development of ...
Christian Oehlwein, Lucas Netzel, Lucas Netzel, Katrin Mittmann, Marita Oehlwein, Walter J. Schulz-Schaeffer   +5 more
doaj   +1 more source

Anti-oxidants in Parkinson's disease therapy: a critical point of view [PDF]

, 2016
Parkinson's disease (PD) is a degenerative neurological syndrome, which is characterized by the preferential death of dopaminergic (DAergic) neurons in the SubstantiaNigra.
Beltramini, Mariano, Bisaglia, Marco, Bubacco, Luigi, Filograna, Roberta   +3 more
core   +2 more sources